Telomerase in Cancer Therapeutics

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• Telomerase is typically silent in normal human tissues but reactivated in most human cancers.
• This reactivation makes telomerase a nearly universal target for cancer therapy.

Purpose of the Study:

• To review preclinical and clinical advancements in targeting telomerase for cancer treatment.
• To discuss various therapeutic approaches and their pros and cons.

Main Methods:

• Review of direct telomerase inhibitors.
• Analysis of G-quadruplex DNA-interacting ligands.
• Evaluation of telomerase-based vaccine platforms.
• Assessment of telomerase promoter-driven attenuated viruses.
• Examination of telomerase-mediated telomere targeting strategies.

Main Results:

• Imetelstat, a telomerase inhibitor, has received FDA approval.
• Several other telomerase-targeting approaches are in late-stage clinical development.
• The review details the advantages and disadvantages of major therapeutic strategies.

Conclusions:

• Targeting telomerase remains a promising strategy in oncology.
• Diverse therapeutic modalities are advancing, offering new hope for cancer patients.
• Continued research and development are crucial for optimizing telomerase-targeted therapies.